消息

The granted patent covers the DRP methods for predicting clinical benefit from stenoparib based on gene-expression profiles derived from tumor samples, as well as methods for selecting patients most likely to benefit from stenoparib treatment using the stenoparib DRP test. This protection is crucial for the company's strategy to develop and commerc...

全文

Allarity Therapeutics, Inc. (NASDAQ: ALLR) has announced that the Japan Patent Office has granted a key patent covering its proprietary stenoparib-specific Drug Response Predictor (DRP) companion diagnostic. The patent, Japanese Patent No. 7917283, provides protection in Japan into 2039. This development is significant as it secures patent protecti...

全文

Over the last three years XEL has grown 41.5%. The current share price of about $74 aligns with a Dividend Discount Model intrinsic value that assumes a moderate 3.7% dividend growth next period. The valuation, therefore, is largely premised on projected dividend expansion, although it depends on growth, margin, and earnings assumptions that may no...

全文

XEL’s market cap is $47.2 billion. The stock has fallen 10.7% from its 52‑week high of $84.23 and 3.5% over the past three months, yet it has outperformed the State Street Utilities Select Sector SPDR ETF (XLU) during the same period. YTD, XEL has risen 2.2% while XLU has declined marginally. Analysts maintain a “Strong Buy” consensus among 18 anal...

全文

Xcel Energy Inc. (NASDAQ:XEL) declared a total dividend of $0.59 per share, with an ex‑dividend date of 2026‑09‑15 and payment on 2026‑10‑20. The 12‑month trailing dividend yield stands at 3.11%, rising to a forward yield of 3.19%. Dividend growth has been robust: 5.30% annually over the past three years, 5.90% over five years, and 6.10% across a d...

全文

Immunovant's current share price is a subject of debate among investors, with some questioning whether the valuation aligns with the company's book value. The stock has delivered strong long-term returns, returning 337.4% over the past 5 years, but this raises concerns about its underlying equity. Recent physician interest in Immunovant's FcRn inhi...

全文

Immunovant's (IMVT) recent trading has been mixed, with a short-term decline of 4.8% over the past week and 10.7% over the past month, but longer-term gains remain strong, with a 1-year total shareholder return of 140.6%. The stock's fair value is estimated at $48.07, suggesting it is currently undervalued by 22%. This valuation is based on long-te...

全文

Tooru is now assessing potential acquisitions, targeting wellness and natural-product businesses that fit its existing portfolio and serve similar consumer demographics. The company aims to pursue acquisitions that can benefit from its manufacturing capabilities. Looking ahead to the second half of 2026, Livingston identified three priorities: incr...

全文

Tooru PLC's half-year performance was highlighted by CEO Scott Livingston, who discussed the company's growth across OAF and Pulsin, as well as its acquisition strategy for the second half of 2026. The company generated over £1 million of EBITDA from its operating businesses in the first half, with OAF gaining traction through increased distributio...

全文

The partnership is expected to strengthen energy resilience and support evolving energy needs across Southeast Europe. In 2025, METLEN reported consolidated revenue of €7.11 billion, EBITDA of €753 million and a net profit of €314 million. METLEN is listed on the London and Athens stock exchanges and is a constituent of the FTSE 100 and Dow Jones B...

全文